The Peter Chew Statin Management Formula for Cancer Prevention: How Dose-Mechanism Balance Explains Conflicting Research Results

Statin therapy has produced contradictory results regarding cancer risk across decades of research. Some studies demonstrate cancer prevention with hazard ratios of 0.51-0.75, while others report increased cancer incidence with 25-97% elevated risk, and many show no effect. This article demonstrates that dose determines cancer outcomes through differential mevalonate pathway blockade. Low doses (27-34% LDL reduction) achieve beneficial mechanism blocks that prevent cancer while minimizing harmful blocks. High doses (54-60% LDL reduction) maximize both beneficial and harmful blocks, with harmful effects dominating to cause cancer. The Peter Chew Statin Management Method calculates optimum dose to maintain cardiovascular protection while minimizing cancer risk through precise dose mechanism balance.